In NSCLC, it has been reported that EGFR mutation status [31] and tumor PD-L1 expression [32–34] are associated with the efficacy of EGFR-TKIs, but there is not enough information regarding this association in pulmonary sarcomatoid carcinoma. This evidence concerns the gene EGFR and non-small cell lung carcinoma.